Subscribe to our emails!

Enter your email address below to receive the latest information about new products, promotions, and more.





Subscribe!
Products
Applications
Techniques
General Purpose DNA Delivery

 

Introducing DNA-In, a new generation of universal transfection reagent for primary and cultured cell lines

DNA-In™ reagent is the newest generation transfection product developed by the lead members of the scientific team that invented the Lipofectamine® and Lipofectamine® 2000. A novel cationic transfection reagent that balances high transfection and expression levels with low toxicity, DNA-In™ works on a very broad range of adherent cells, including most passaged cell lines and many primary cells.

Features

  • Fast, simple, easy-to-follow protocol
  • One-step process: simply add DNA-In™ Reagent to diluted DNA, incubate 10 minutes, and add to pre-plated cells
  • Minimal toxicity - no need to replace medium after transfection


Superior Tranfection Efficiency

The development of DNA-In™ involved extensive validation testing in a range of primary and cultured cells. In head-to-head comparison studies, DNA-In™ consistently outperformed the * Lipofectamine® 2000 transfection reagent.


 DNA-In outperforms Lipofectamine 2000 in GFP transfection

 DNA-In outperforms Lipofectamine 2000 in GFP transfection

 DNA-In outperforms Lipofectamine 2000 in GFP transfection

Cells were transfected with a plasmid, containing EmeraldGFP behind an EF1α promoter, with either DNA-In™ or Lipofectamine®2000, at several different lipid:DNA ratios and examined ~44 hours post-transfection. Representative images of the best conditions for each transfection reagent are shown.


Low Cell Toxicity 

DNA-In has a significantly lower cell toxicity compared to traditional transfection reagents such as Lipofectamine and Lipofectamine 2000.  In the many cell lines tested, DNA-In shows a broad range of effective dosage while maintaining minimal cell toxicity.  This low cell toxicity allows a larger dosage and time window for optimized transfection results.

The following charts show side-by-side comparisons of DNA-In and Lipofectamine 2000 (LF2K) in commonly used cell lines and primary cells:

DNA-In and Lipofectamine 2000 comparison in 293 cells

In 293 cells, DNA-In maintains high cell viability throughout the tested dosage range, while LF2K has a significant cell toxicity issue when used in dosages over 3 ul.


DNA-In and Lipofectamine 2000 comparison in A549 cells

In A549 cells, DNA-In has a significantly higher transfection efficiency and a lower cell toxicity while LF2K performs poorly in both parameters.


DNA-In and Lipofectamine 2000 comparison in human fibroblasts

In human fibroblast cells, DNA-In has a significantly higher transfection efficiency and a lower cell toxicity while LF2K performs poorly in both parameters.


DNA-In and Lipofectamine 2000 comparison in Hela cells
In Hela cells, DNA-In has a significantly higher transfection efficiency and a lower cell toxicity while LF2K performs poorly in both parameters.
DNA-In and Lipofectamine 2000 in HepG2 cells
In HepG2 cells, DNA-In has a significantly higher transfection efficiency and a lower cell toxicity while LF2K performs poorly in both parameters.
DNA-In and Lipofectamine 2000 comparison in MCF7 cells
In MCF7 cells, DNA-In has a significantly higher transfection efficiency and a lower cell toxicity while LF2K transfection efficiency is lower and is toxic when used in dosages higher than 2 ul.

 

* Lipofectamine® is a registered trademark of Life Technologies, Inc.

 

There are no products to list in this category.
General, Purpose, DNA, Delivery, Transfection, Reagents
©BioAstrum Corporation. All Rights Reserved 2014.
Google+